Quantum BioPharma Executive Discusses Lucid-MS Drug Candidate and unbuzzd on Podcast

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is leveraging executive thought leadership to communicate its drug development strategy. Executive co-chairman and co-founder Anthony Durkacz recently appeared as a guest on the BioMedWire Podcast to discuss the company's lead multiple sclerosis drug candidate, Lucid-MS, and its growth strategy.

During the podcast, Durkacz outlined the company's approach to advancing Lucid-MS through clinical development. Lucid-MS is designed to address neurodegenerative processes in multiple sclerosis, a chronic condition affecting the central nervous system. The executive provided insights into the drug's mechanism of action and the company's plans for upcoming trials, emphasizing the potential to modify disease progression.

Durkacz also provided an update on unbuzzd, Quantum BioPharma's clinically validated alcohol metabolism accelerator. The product is designed to help individuals sober up faster by accelerating the breakdown of alcohol in the body. According to the company, unbuzzd has received positive feedback and is being positioned as a commercial product in the wellness market.

The podcast appearance reflects a broader trend in biotechnology communications, where executives use interviews to explain complex science and corporate strategy. Quantum BioPharma focuses on developing treatments for neurodegenerative, metabolic, and alcohol-misuse disorders, with Lucid-MS and unbuzzd representing key assets. The company's strategy includes leveraging partnerships and intellectual property to advance its pipeline.

Investors and industry observers can find more information about Quantum BioPharma in the company's newsroom at https://ibn.fm/QNTM. The company's forward-looking statements are subject to risks and uncertainties as detailed in its filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.